Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of
coronavirus disease 2019 (COVID-19). SARS-CoV-2 has been spreading worldwide since …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …

The COVID-19 therapeutic landscape rapidly evolved throughout the course of the SARS-
CoV-2 pandemic. However, the ingenuity of our community quickly coalesced to identify …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide
severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a …

Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome
(SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social …

The high transmissibility and rapid global spread of SARS-CoV-2 since 2019 has led to a
huge burden on healthcare worldwide. Anti-SARS-CoV-2 neutralizing antibodies play an …

Effective treatments specific for COVID-19 are still lacking. In the setting of passive
immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of …

Neutralizing antibodies (NAbs) are central players in the humoral immunity that defends the
body from SARS-CoV-2 infection by blocking viral entry into host cells and neutralizing their …

The epidemic of corona virus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome Coronavirus 2 and its variants of concern (VOCs) has been ongoing for over 3 …

Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management …